User profiles for Laurence Klotz
 | laurence klotzProfessor of Surgery, University of Toronto Verified email at sunnybrook.ca Cited by 41055 |
[HTML][HTML] MRI-targeted or standard biopsy for prostate-cancer diagnosis
Background Multiparametric magnetic resonance imaging (MRI), with or without targeted
biopsy, is an alternative to standard transrectal ultrasonography–guided biopsy for prostate-…
biopsy, is an alternative to standard transrectal ultrasonography–guided biopsy for prostate-…
Active surveillance for prostate cancer: a systematic review of the literature
CONTEXT: Prostate cancer (PCa) remains an increasingly common malignancy worldwide.
The optimal management of clinically localized, early-stage disease remains unknown, and …
The optimal management of clinically localized, early-stage disease remains unknown, and …
[PDF][PDF] Long-term follow-up of a large active surveillance cohort of patients with prostate cancer
L Klotz, D Vesprini, P Sethukavalan, V Jethava… - J Clin …, 2015 - pureadmin.qub.ac.uk
… Klotz L: Active surveillance for prostate cancer: For whom? J Clin Oncol 23:8165-8169,
2005 3. … Zhang L, Loblaw A, Klotz L: Modeling prostate specific antigen kinetics in …
2005 3. … Zhang L, Loblaw A, Klotz L: Modeling prostate specific antigen kinetics in …
Increasing hospital admission rates for urological complications after transrectal ultrasound guided prostate biopsy
…, R Saskin, Y Lee, Y Liu, C Law, LH Klotz… - The Journal of …, 2010 - auajournals.org
Purpose : Transrectal ultrasound guided prostate biopsy is widely used to confirm the
diagnosis of prostate cancer. The technique has been associated with significant morbidity in a …
diagnosis of prostate cancer. The technique has been associated with significant morbidity in a …
Clinically localized prostate cancer: AUA/ASTRO/SUO guideline. Part II: recommended approaches and details of specific care options
…, SJ Freedland, K Greene, LH Klotz… - The Journal of …, 2018 - auajournals.org
Purpose : This guideline is structured to provide a clinical framework stratified by cancer
severity to facilitate care decisions and guide the specifics of implementing the selected …
severity to facilitate care decisions and guide the specifics of implementing the selected …
Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT)
…, JM Gaziano, DD Karp, MM Lieber, PJ Walther, L Klotz… - Jama, 2011 - jamanetwork.com
Context The initial report of the Selenium and Vitamin E Cancer Prevention Trial (SELECT)
found no reduction in risk of prostate cancer with either selenium or vitamin E supplements …
found no reduction in risk of prostate cancer with either selenium or vitamin E supplements …
[PDF][PDF] Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer
… Provision of study materials or patients: Laurence Klotz, … Klotz L: Active surveillance for
prostate cancer: For whom? J Clin Oncol 23:8165-8169, 2005 7. Remzi M, Fong YK …
prostate cancer: For whom? J Clin Oncol 23:8165-8169, 2005 7. Remzi M, Fong YK …
A prospective, randomised EORTC intergroup phase 3 study comparing the oncologic outcome of elective nephron-sparing surgery and radical nephrectomy for low …
…, V Matveev, A Bono, A Borkowski, M Colombel, L Klotz… - European urology, 2011 - Elsevier
BACKGROUND: Nephron-sparing surgery (NSS) can safely be performed with slightly higher
complication rates than radical nephrectomy (RN), but proof of oncologic effectiveness is …
complication rates than radical nephrectomy (RN), but proof of oncologic effectiveness is …
Clinically localized prostate cancer: AUA/ASTRO/SUO guideline. Part I: risk stratification, shared decision making, and care options
…, SJ Freedland, K Greene, LH Klotz… - The Journal of …, 2018 - auajournals.org
Purpose : This guideline is structured to provide a clinical framework stratified by cancer
severity to facilitate care decisions and guide the specifics of implementing the selected …
severity to facilitate care decisions and guide the specifics of implementing the selected …
The efficacy and safety of degarelix: a 12‐month, comparative, randomized, open‐label, parallel‐group phase III study in patients with prostate cancer
L Klotz, L Boccon‐Gibod, ND Shore… - BJU …, 2008 - Wiley Online Library
OBJECTIVE To evaluate the efficacy and safety of degarelix, a new gonadotrophin‐releasing
hormone (GnRH) antagonist (blocker), vs leuprolide for achieving and maintaining …
hormone (GnRH) antagonist (blocker), vs leuprolide for achieving and maintaining …
